AIIMS Jodhpur · AIIMS/JDH/PED/2026/685
Efficacy and safety of substitution of bleomycin by low dose nivolumba in ABVD (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine) backbone chemotherapy in newly diagnosed advanced-stage pediatric Hodgkin Lymphoma: A phase II/III, multicentric, open-label, randomized controlled trial 2026
Applications open 2 days left
All India Institute of Medical Sciences, Jodhpur is recruiting Efficacy and safety of substitution of bleomycin by low dose nivolumba in ABVD (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine) backbone chemotherapy in newly diagnosed advanced-stage pediatric Hodgkin Lymphoma: A phase II/III, multicentric, open-label, randomized controlled trial. Applications opened 02 September and close 10 September 2026. Advertisement AIIMS/JDH/PED/2026/685.
This drive does not publish a state-by-state vacancy table, or we have not been able to read one from it yet — so this page does not show one.
| Applications open | 02 Sep 2026 |
|---|---|
| Last date | 10 Sep 2026 |
| Age | up to 30 years |
| Age reckoned as on | 10 Sep 2026 |
| Qualification | Graduate in Science/relevant subjects from a recognized university/Institution |
| Fee | not read yet |
| Advertisement | AIIMS/JDH/PED/2026/685 |
| Pay | Rs. 20,000/- + 18% HRA (23,600/-) per month |
| Selection | Walk-In-Interview → written examination |
| Documents | Passport-size photograph; essential qualifications certificates; experience certificates; No Objection Certificate |
Blanks are ours, not the document's. Every filled value was read from the notification linked below; anything marked not read yet is a gap in our reading, not a field the recruiter left empty.
1788414536_lymphoma recruitment letter 02 September.pdf
— the official AIIMSJ notification (aiimsj-table).Not checked. No state-by-state table could be read from this document, so there was no arithmetic to reconcile. The dates and identifiers above come from the document itself.
Fetched 08 Sep 2026, 01:04 UTC.